INSULIN LISPRO MARKET ANALYSIS

Market News

Insulin Lispro Market New product launches including year

• Lyumjev (insulin lispro-aabc injection) - Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) approval for an expanded label rapid-acting insulin, Lyumjev (insulin lispro-aabc injection) in August 2021. The drugs are available in a quantity of 100 units/mL. These are indicated to improve glycemic control in adults with type 1 and type 2 diabetes, to include administration via continuous subcutaneous insulin infusion (CSII) with an insulin pump.
• Lyumjev (insulin lispro-aabc injection) - Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) approval for rapid-acting insulin, Lyumjev (insulin lispro-aabc injection) in June 2020. The drugs are available in a quantity of insulin lispro-aabc injection, 100 units/mL and 200 units/mL. Lyumjev is a novel formulation of insulin lispro, developed to speed the absorption of insulin into the blood stream and reduce A1C levels

Acquisition and partnerships in Insulin Lispro Market

• Eli Lilly and Company (Lilly) and Ypsomed: In 2020, Eli Lilly and Company (Lilly), U.S. based global pharmaceutical company and Ypsomed, Swiss based leading developer and manufacturer of injection and infusion systems developing company, entered into a non-exclusive, global partnership to create and commercialize automated insulin delivery systems. The collaboration aimed to integrate Lilly's insulin products, including Insulin Lispro, with Ypsomed's insulin pump technologies to improve insulin therapy options for people with diabetes.
• Eli Lilly and Company (Lilly) and Cipla Limited: In 2021, Lilly and Cipla, India based Global generic pharmaceutical company, entered into a strategic partnership in India to enhance the reach of Lilly’s diabetes products:  Humalog [Insulin Lispro I.P. (rDNA Origin) injection] and Trulicity (Dulaglutide). Lilly will transfer its rights in India to sell, promote, and distribute the aforesaid two Lilly Diabetes products, Humalog & Trulicity to Cipla, subject to all regulatory approvals.
• Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. and  Tonghua Dongbao Pharmaceutical Co., Ltd.: In 2021 Meitheal Pharmaceuticals, Inc. (Meitheal), a parent company of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (NKF), announced a licensing agreement with Tonghua Dongbao Pharmaceutical Co., Ltd, China-based company, principally engaged in the research and development, manufacture and distribution of pharmaceuticals company, to commercialize three insulin biosimilars---insulin aspart, insulin lispro, and insulin glargine in the U.S.